vs
Side-by-side financial comparison of APA Corporation (APA) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
APA Corporation is the larger business by last-quarter revenue ($2.2B vs $1.2B, roughly 1.8× Jazz Pharmaceuticals plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs 15.0%, a 2.0% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs -24.3%). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 1.4%).
APA Corporation, a holding company for Apache Corporation, an American company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in Houston.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
APA vs JAZZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $1.2B |
| Net Profit | $331.0M | $203.5M |
| Gross Margin | — | — |
| Operating Margin | 32.5% | 21.2% |
| Net Margin | 15.0% | 17.0% |
| Revenue YoY | -24.3% | 10.1% |
| Net Profit YoY | -22.1% | 6.5% |
| EPS (diluted) | $0.79 | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2B | $1.2B | ||
| Q3 25 | $2.3B | $1.1B | ||
| Q2 25 | $2.3B | $1.0B | ||
| Q1 25 | $2.7B | $897.8M | ||
| Q4 24 | $2.9B | $1.1B | ||
| Q3 24 | $2.7B | $1.1B | ||
| Q2 24 | $2.8B | $1.0B | ||
| Q1 24 | $2.1B | $902.0M |
| Q4 25 | $331.0M | $203.5M | ||
| Q3 25 | $205.0M | $251.4M | ||
| Q2 25 | $603.0M | $-718.5M | ||
| Q1 25 | $418.0M | $-92.5M | ||
| Q4 24 | $425.0M | $191.1M | ||
| Q3 24 | $-223.0M | $215.1M | ||
| Q2 24 | $541.0M | $168.6M | ||
| Q1 24 | $212.0M | $-14.6M |
| Q4 25 | 32.5% | 21.2% | ||
| Q3 25 | 33.7% | 5.1% | ||
| Q2 25 | 31.8% | -65.6% | ||
| Q1 25 | 31.9% | -6.2% | ||
| Q4 24 | 31.4% | 17.5% | ||
| Q3 24 | -5.2% | 24.7% | ||
| Q2 24 | 34.4% | 19.5% | ||
| Q1 24 | 32.2% | 7.3% |
| Q4 25 | 15.0% | 17.0% | ||
| Q3 25 | 9.0% | 22.3% | ||
| Q2 25 | 26.0% | -68.7% | ||
| Q1 25 | 15.4% | -10.3% | ||
| Q4 24 | 14.6% | 17.6% | ||
| Q3 24 | -8.1% | 20.4% | ||
| Q2 24 | 19.0% | 16.5% | ||
| Q1 24 | 9.9% | -1.6% |
| Q4 25 | $0.79 | $3.34 | ||
| Q3 25 | $0.57 | $4.08 | ||
| Q2 25 | $1.67 | $-11.74 | ||
| Q1 25 | $0.96 | $-1.52 | ||
| Q4 24 | $0.97 | $2.97 | ||
| Q3 24 | $-0.60 | $3.42 | ||
| Q2 24 | $1.46 | $2.49 | ||
| Q1 24 | $0.44 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $516.0M | $1.4B |
| Total DebtLower is stronger | $4.3B | $5.4B |
| Stockholders' EquityBook value | $6.1B | $4.3B |
| Total Assets | $17.8B | $11.7B |
| Debt / EquityLower = less leverage | 0.70× | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $516.0M | $1.4B | ||
| Q3 25 | $475.0M | $1.3B | ||
| Q2 25 | $107.0M | $1.2B | ||
| Q1 25 | $67.0M | $1.9B | ||
| Q4 24 | $625.0M | $2.4B | ||
| Q3 24 | $64.0M | $2.2B | ||
| Q2 24 | $160.0M | $1.4B | ||
| Q1 24 | $102.0M | $1.4B |
| Q4 25 | $4.3B | $5.4B | ||
| Q3 25 | $4.3B | $5.4B | ||
| Q2 25 | $4.3B | $5.4B | ||
| Q1 25 | $5.2B | $5.4B | ||
| Q4 24 | $6.0B | $6.1B | ||
| Q3 24 | $6.4B | $6.1B | ||
| Q2 24 | $6.7B | $5.7B | ||
| Q1 24 | $5.2B | $5.7B |
| Q4 25 | $6.1B | $4.3B | ||
| Q3 25 | $6.0B | $4.0B | ||
| Q2 25 | $5.9B | $3.7B | ||
| Q1 25 | $5.4B | $4.2B | ||
| Q4 24 | $5.3B | $4.1B | ||
| Q3 24 | $5.1B | $4.2B | ||
| Q2 24 | $5.4B | $3.8B | ||
| Q1 24 | $2.6B | $3.7B |
| Q4 25 | $17.8B | $11.7B | ||
| Q3 25 | $17.7B | $11.4B | ||
| Q2 25 | $18.1B | $10.9B | ||
| Q1 25 | $18.5B | $11.5B | ||
| Q4 24 | $19.4B | $12.0B | ||
| Q3 24 | $19.4B | $12.3B | ||
| Q2 24 | $20.2B | $11.4B | ||
| Q1 24 | $15.0B | $11.3B |
| Q4 25 | 0.70× | 1.24× | ||
| Q3 25 | 0.72× | 1.35× | ||
| Q2 25 | 0.73× | 1.45× | ||
| Q1 25 | 0.96× | 1.29× | ||
| Q4 24 | 1.13× | 1.49× | ||
| Q3 24 | 1.25× | 1.47× | ||
| Q2 24 | 1.24× | 1.52× | ||
| Q1 24 | 1.99× | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $808.0M | $362.5M |
| Free Cash FlowOCF − Capex | — | $345.8M |
| FCF MarginFCF / Revenue | — | 28.9% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 2.44× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $808.0M | $362.5M | ||
| Q3 25 | $1.5B | $474.6M | ||
| Q2 25 | $1.2B | $88.9M | ||
| Q1 25 | $1.1B | $429.8M | ||
| Q4 24 | $1.0B | $398.6M | ||
| Q3 24 | $1.3B | $398.7M | ||
| Q2 24 | $877.0M | $331.4M | ||
| Q1 24 | $368.0M | $267.2M |
| Q4 25 | — | $345.8M | ||
| Q3 25 | — | $459.4M | ||
| Q2 25 | — | $75.9M | ||
| Q1 25 | — | $415.9M | ||
| Q4 24 | — | $385.3M | ||
| Q3 24 | — | $388.0M | ||
| Q2 24 | — | $324.3M | ||
| Q1 24 | — | $260.3M |
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 40.8% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | — | 35.4% | ||
| Q3 24 | — | 36.8% | ||
| Q2 24 | — | 31.7% | ||
| Q1 24 | — | 28.9% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | 2.44× | 1.78× | ||
| Q3 25 | 7.12× | 1.89× | ||
| Q2 25 | 1.96× | — | ||
| Q1 25 | 2.62× | — | ||
| Q4 24 | 2.44× | 2.09× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | 1.62× | 1.97× | ||
| Q1 24 | 1.74× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APA
| Oil And Gas Excluding Purchased | $1.7B | 76% |
| Oil And Gas Purchased | $323.0M | 15% |
| Oil Reserves | $114.0M | 5% |
| Other | $72.0M | 3% |
| Natural Gas Reserves | $30.0M | 1% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
